Non-selective non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular risk
- PMID: 24189757
Non-selective non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular risk
Abstract
NSAIDs are largely used for the treatment of a huge variety of clinical conditions in order to relieve symptoms related to inflammation.The use of NSAIDs is associated with a potential increased risk of gastrointestinal and cardiovascular complications.The cardiovascular risk related to NSAIDs administration is often underestimated and it is frequently believed to be less important than the gastrointestinal risk. Adverse effects of NSAIDs are specifically related to their underlying mechanisms of action.The most plausible mechanism underlying the cardiovascular risk of NSAIDs has been identified in the profound inhibition of COX-2-dependent PGI2 in the presence of incomplete and intermittent inhibition of platelet COX-1. Nevertheless, the cardiovascular risk related to the use of NSAIDs is not only due to the COX-2 selectivity. An important determinant of the clinical effects of NSAIDs depends on the pharmacokinetic features of the different drugs such as half-life, and type of formulations, which can influence the extent and duration of patient exposure to COXisozyme inhibition. The aim of this review is to analyse the mechanisms behind the cardiovascular risk of different NSAIDs.
Similar articles
-
Dual acting anti-inflammatory drugs: a reappraisal.Pharmacol Res. 2001 Dec;44(6):437-50. doi: 10.1006/phrs.2001.0872. Pharmacol Res. 2001. PMID: 11735348 Review.
-
Variability in the response to non-steroidal anti-inflammatory drugs: mechanisms and perspectives.Basic Clin Pharmacol Toxicol. 2014 Jan;114(1):56-63. doi: 10.1111/bcpt.12117. Epub 2013 Sep 3. Basic Clin Pharmacol Toxicol. 2014. PMID: 23953622 Review.
-
Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale.Cardiol Rev. 2010 Jul-Aug;18(4):204-12. doi: 10.1097/CRD.0b013e3181ce1521. Cardiol Rev. 2010. PMID: 20539104 Review.
-
Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.J Clin Pharm Ther. 2017 Feb;42(1):27-38. doi: 10.1111/jcpt.12484. Epub 2016 Dec 26. J Clin Pharm Ther. 2017. PMID: 28019014 Review.
-
Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?Lancet. 2007 Dec 22;370(9605):2138-51. doi: 10.1016/S0140-6736(07)61909-6. Lancet. 2007. PMID: 18156036 Review.
Cited by
-
Cardiorenal Safety of OTC Analgesics.J Cardiovasc Pharmacol Ther. 2018 Mar;23(2):103-118. doi: 10.1177/1074248417751070. J Cardiovasc Pharmacol Ther. 2018. PMID: 29421936 Free PMC article. Review.
-
Celecoxib use and circulating oxylipins in a colon polyp prevention trial.PLoS One. 2018 Apr 26;13(4):e0196398. doi: 10.1371/journal.pone.0196398. eCollection 2018. PLoS One. 2018. PMID: 29698447 Free PMC article. Clinical Trial.
-
Pharmacological evaluation and preparation of nonsteroidal anti-inflammatory drugs containing an N-acyl hydrazone subunit.Int J Mol Sci. 2014 Apr 4;15(4):5821-37. doi: 10.3390/ijms15045821. Int J Mol Sci. 2014. PMID: 24714090 Free PMC article.
-
Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications.Ther Adv Drug Saf. 2017 Jun;8(6):173-182. doi: 10.1177/2042098617690485. Epub 2017 Feb 10. Ther Adv Drug Saf. 2017. PMID: 28607667 Free PMC article. Review.
-
Future directions for the management of pain in osteoarthritis.Int J Clin Rheumtol. 2014 Apr;9(2):197-276. doi: 10.2217/ijr.14.10. Int J Clin Rheumtol. 2014. PMID: 25018771 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials